Last updated: February 20, 2026
What is the drug associated with NDC 70000-0253?
NDC 70000-0253 corresponds to Copaxone (glatiramer acetate), marketed primarily for multiple sclerosis (MS). The drug has been branded and also available in generic forms since patent expiration.
Market Size and Dynamics
Current Market Landscape
- Global Multiple Sclerosis Market: Valued at approximately $22 billion in 2022. Expected to grow at a compound annual growth rate (CAGR) of 5% through 2030 due to rising prevalence.
- U.S. MS Market: Accounts for nearly 50% of global sales, estimated at $11 billion in 2022.
- Copaxone Market Share: Held around 30% of the MS treatment market before patent expiration, with sales approaching $4 billion globally.
Key Competitors
- Aubagio (teriflunomide): Competitive in oral MS therapeutics.
- Tecfidera (dimethyl fumarate): Oral therapy with a significant market share.
- Gilenya (fingolimod): First oral medication, holds approximately 10-15% of MS market.
Distribution of Market Segments
| Segment |
Market Share (2022) |
Notes |
| Injectables (e.g., Copaxone) |
60% |
Phased decline due to orally administered drugs |
| Orals |
35% |
Rapidly increasing due to convenience |
| Infusions |
5% |
Limited to certain patient populations |
Patent and Regulatory Landscape
- Patent Expiry: Gained clearance for generic versions in late 2018.
- Regulatory Status:
- Original brand (Teva Pharmaceutical): Patents upheld until 2018 in several territories.
- Generics approved in the U.S. and Europe post-2018.
Price Trends and Projections
Historical Pricing Data
| Year |
Brand Price (per 30-month supply) |
Generic Price (per 30-month supply) |
| 2018 |
$60,000 |
$20,000 |
| 2020 |
$55,000 |
$17,000 |
| 2022 |
$50,000 |
$15,000 |
Price Drivers
- Patent expiration led to a sharp drop in generic prices.
- Market competition has increased, pressuring prices downward.
- Healthcare policy: Payers and regulators seek to lower costs, favoring generics and biosimilars.
Forecasted Prices (2025-2030)
- Brand Cost: Expected to decline gradually to around $40,000 per 30-month supply.
- Generics: Likely to stabilize around $10,000-$12,000 per 30-month supply, reflecting increased competition.
| Year |
Brand Price (approximate) |
Generic Price (approximate) |
| 2025 |
$45,000 |
$11,000 |
| 2030 |
$40,000 |
$10,000 |
Revenue Projections
By 2030, the MS injectable market including Copaxone is projected to decline by approximately 20% from peak sales of 2020, driven by switch to oral therapies and biosimilars. Sales for Copaxone branded form could reduce to around $2-3 billion globally, with generics capturing a larger share.
Conclusion
- The market for glatiramer acetate is contracting, primarily driven by competition from oral MS drugs and biosimilars.
- Price erosion is expected, with generic versions costing approximately 40-50% less than originator brand.
- Continued growth hinges on market share retention and new formulations or indications.
Key Takeaways
- Copaxone faces declining market share amid growing oral therapies and biosimilars.
- Price projections show significant reductions for generics, stabilizing around $10,000-$12,000 per supply.
- Total sales are expected to decline from peak levels, but the overall MS market continues to grow.
FAQs
1. What are the main competitors to Copaxone?
Oral therapies like Tecfidera and Gilenya dominate, with biosimilars increasing pressure on price and market share.
2. How have pricing trends evolved post-generic entry?
Generic prices dropped by roughly 50% initially and have since stabilized amid increasing competition.
3. Will branded Copaxone remain relevant?
Brands retain some market share, especially for specific patient groups, but face declining sales due to generics.
4. What factors could influence future prices?
Regulatory changes, new biosimilar approvals, or inclusion of innovative delivery methods could alter pricing trajectories.
5. How is the global market expected to evolve?
Growth will be driven by increasing MS prevalence, especially in emerging markets, despite price pressure.
References
[1] IQVIA. (2022). Global Multiple Sclerosis Market Data.
[2] MarketWatch. (2022). MS Therapeutics Market Size and Trends.
[3] FDA. (2019). Generic Drug Approvals.
[4] Teva Pharmaceuticals. (2022). Copaxone Sales Data.
[5] EvaluatePharma. (2023). Healthcare Market Projections.
